Gsk (GSK) Long-Term Debt Issuances (2009 - 2025)

Gsk's Long-Term Debt Issuances history runs 13 years deep, the most recent figure standing at $2.5 billion for Q1 2025.

• In Q1 2025, Long-Term Debt Issuances changed N/A year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $14.9 billion (changed N/A YoY), while the FY2025 annual figure was $2.6 billion, up 89.89% from the prior year.
• Long-Term Debt Issuances was $2.5 billion for Q1 2025 at Gsk, up from -$18.6 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $12.4 billion in Q1 2022 to a low of -$1.5 billion in Q4 2021.
• Historically, Long-Term Debt Issuances has averaged $3.3 billion across 4 years, with a median of $1.3 billion in 2023.
• Biggest YoY gain for Long-Term Debt Issuances was 2808.87% in 2021; the steepest drop was 2808.87% in 2021.
• A 4-year view of Long-Term Debt Issuances shows it stood at -$1.5 billion in 2021, then soared by 903.05% to $12.4 billion in 2022, then sank by 100.15% to -$18.6 million in 2023, then soared by 13752.22% to $2.5 billion in 2025.
• The last three Long-Term Debt Issuances figures came in at $2.5 billion (Q1 2025), -$18.6 million (Q4 2023), and $12.4 billion (Q1 2022), per Business Quant data.